- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
GRF
MCE
Week ended 07 Aug 2026
Weekly Investor Report
Grifols, S.A. · Healthcare · Drug Manufacturers - General
Latest close
10.18 EUR
1.3%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 6.0% above the Trend Line and sits at 39.2% of its 52-week range. The latest completed week returned 1.3%, after a 14.3% four-week move. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
45
out of 100
Latest Close
10.18 EUR
7 Aug 2026
1W Return
1.3%
latest completed week
4W Return
14.3%
short-term follow-through
12W Return
12.9%
quarterly tape
Trend Breadth
25.0%
13 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.3%
Latest completed week; four-week move 14.3%.
Indicator stack
14/95
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
7 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 6.0% above the Trend Line and sits at 39.2% of its 52-week range. The latest completed week returned 1.3%, after a 14.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2612-week average 0.12
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.26Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 14.3% over four weeks, 12.9% over 12 weeks, and -20.5% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year13
Trend breadth25.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.00Latest activity-pressure read.
Pressure change337.6%Four-week change in activity pressure.
Leadership-16.97Latest relative-leadership reading.
RS change38.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 7 relevant articles.
1 positive · 5 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-21.0%Distance below the 52-week high.
13-week volatility2.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher12 of 2614 weeks finished lower.
Best week+8.0%Week of 17 Apr.
Worst week-8.4%Week of 13 Mar.
Latest week+1.3%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains8
Flat weeks0
Modest losses9
Sharp losses5
Recent vol2.5%13-week weekly-return volatility.
Base vol3.4%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew2.4% / -3.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorES Healthcare
4-week rank1 / 14
Group average3.0%
Trend breadth35.7%
Trend35.7%active weekly trend signals
MD28.6%positive activity pressure
RS21.4%positive relative leadership
Four-week leaders
IndustryES Drug Manufacturers - General
4-week rank1 / 1
Group average14.3%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD100.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape37/100
Trend, activity pressure, participation, and risk combine to a 37/100 tape read.
Indicator analysis27/100Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.
Activity pressure 0.26; No reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 7 relevant articles.
Is Grifols (BME:GRF) A Bargain On Mixed Half Year Earnings? Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 10.18 EUR | 1.3% | 9.59 EUR | 10.15 EUR | 1.00 | -16.97 | 6.7M | Off |
| 31 Jul 2026 | 10.04 EUR | 4.0% | 9.64 EUR | 10.16 EUR | 0.74 | -17.38 | 15.3M | Off |
| 24 Jul 2026 | 9.66 EUR | 6.4% | 9.67 EUR | 10.18 EUR | 0.47 | -20.73 | 10.8M | Off |
| 17 Jul 2026 | 9.08 EUR | 2.0% | 9.72 EUR | 10.20 EUR | 0.30 | -24.88 | 9.0M | Off |
| 10 Jul 2026 | 8.90 EUR | -1.3% | 9.78 EUR | 10.23 EUR | 0.23 | -27.79 | 8.1M | Off |
| 3 Jul 2026 | 9.02 EUR | -0.3% | 9.84 EUR | 10.25 EUR | 0.17 | -29.36 | 976.0K | Off |
| 26 Jun 2026 | 9.04 EUR | 0.3% | 9.90 EUR | 10.27 EUR | 0.03 | -28.24 | 1.9M | Off |
| 19 Jun 2026 | 9.02 EUR | 0.8% | 9.95 EUR | 10.29 EUR | 0.03 | -28.70 | 3.2M | Off |
| 12 Jun 2026 | 8.95 EUR | -0.3% | 9.99 EUR | 10.30 EUR | -0.12 | -27.61 | 2.0M | Off |
| 5 Jun 2026 | 8.98 EUR | -2.4% | 10.05 EUR | 10.32 EUR | -0.24 | -26.29 | 1.8M | Off |
| 29 May 2026 | 9.20 EUR | -2.0% | 10.09 EUR | 10.33 EUR | -0.38 | -25.05 | 32.1M | Off |
| 22 May 2026 | 9.38 EUR | 4.1% | 10.16 EUR | 10.35 EUR | -0.74 | -22.28 | 9.2M | Off |
| 15 May 2026 | 9.01 EUR | 1.7% | 10.22 EUR | 10.36 EUR | -0.84 | -24.12 | 13.3M | Off |
| 8 May 2026 | 8.86 EUR | -0.2% | 10.32 EUR | 10.37 EUR | -0.84 | -26.75 | 11.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.